BioSpace News Archive

Altimmune, Inc. today announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at the American Diabetes Association’s (ADA) 84th Scientific Sessions, to be held in Orlando, FL from June 21-24, 2024.

CG Oncology, Inc. announced that it has initiated an Expanded Access Program for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette-Guerin and meet certain program eligibility criteria.

Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD), is pleased to announce that it has been selected to present the data from its latest Alzheimer’s study in an extended 45-minute session at the Alzheimer’s Association International Conference® 2024 (AAIC®).

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL) today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel’s President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024 at 3:00 p.m. ET.

4D Molecular Therapeutics today announced that the Company will present the initial interim 24-week landmark analysis from the Population Extension cohort of the PRISM Phase 2 Clinical Trial evaluating 4D-150 in a broad wet AMD patient population at the ASRS Annual Scientific Meeting being held in Stockholm, Sweden from July 17-20, 2024.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, presented data from a poster presentation at the 66th Annual Scientific Meeting of the American Headache Society (AHS), held June 13-16, 2024.

Petauri announced the addition of two UK-based firms: Mtech Access, a premier full-service global market access solutions provider; and Delta Hat, an experience-led company specializing in the technical aspects of evidence-based value demonstration.

MilliporeSigma and The Michael J. Fox Foundation for Parkinson’s Research (MJFF), are advancing research aimed at slowing progression of Parkinson’s disease (PD).

The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, unveiled a new clinical research laboratory building at its good manufacturing practices lab in Middleton, Wisconsin.